As a business reporter, I write about small businesses opening and closing, manufacturing, food and drink, labor issues and economic data. I particularly love writing about the impact of state and federal policy on local businesses. I also do some education reporting, covering colleges in southeastern Connecticut and regional K-12 issues.
Erica Moser
As a business reporter, I write about small businesses opening and closing, manufacturing, food and drink, labor issues and economic data. I particularly love writing about the impact of state and federal policy on local businesses. I also do some education reporting, covering colleges in southeastern Connecticut and regional K-12 issues.
(0)
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile in 21 heavily pre-treated and immunocompromised patients with steroid-resistant, gastrointestinal-predominant aGvHD following stem cell transplantation
Results in line with previously observed data from a larger patient population treated with MaaT013 as part of an early access program
MaaT013 expected to advance into pivotal Phase 3 program MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD). The study met its primary endpoint of clinical efficacy, demonstrating a combined 33.3% complete response rate (CR) or very good partial response rate (VGPR) at day 28. In addition, the overall response rate (ORR) was 38.1% at day 28 and the be
Today
Rain and snow showers this evening turning to all snow overnight. Low 34F. Winds SW at 10 to 20 mph. Chance of precip 100%. Snow accumulating 1 to 3 inches..
Tonight
Rain and snow showers this evening turning to all snow overnight. Low 34F. Winds SW at 10 to 20 mph. Chance of precip 100%. Snow accumulating 1 to 3 inches. Updated: March 21, 2021 @ 3:45 pm
GIDEON MEYEROWITZ-KATZ
17 MARCH 2021
Vaccines are amazing, life-saving innovations, and the COVID-19 vaccines are no different. As with any medical procedure, there are potential drawbacks to using them, but we know from massive pieces of scientific research that the COVID-19 vaccines are both safe and effective.
And yet, as you have probably heard on the news, for one specific vaccine most of Europe has stopped their rollout. Rather than giving millions of people the AstraZeneca/Oxford (AZ) vaccine against COVID-19, a dozen countries have decided to stop vaccinating due to fears of side-effects.
So I thought I would explain what s happening, and why you probably don t need to worry even if you ve had the AZ vaccine.
March 17, 2021
Maharashtra leads first dose drive
India crossed the 35-million mark on Tuesday after vaccinating 21,17,104 people against coronavirus. The cumulative total now stands at 3,50,64,536, as per the official data of the Ministry of Health and Family Welfare.
The first dose of the vaccine was received by 17,82,553 people while 3,34,551 people received the second dose in the last 24 hours.
The country has so far administered the first dose of the vaccine to 2,88,62,037 people while the second dose has been given to 62,02,499 people.
State-wise tally
Maharashtra leads the first dose vaccination drive as it has vaccinated 28,62,885 people with the first jab so far, closely followed by Rajasthan at 28,62,220 and Uttar Pradesh at 25,10,657.